Subcellular Proteome Analysis Reveals Apoptotic Vulnerability of T-Cell Acute Lymphoblastic Leukemia

Figure 1

The isolation of a Jurkat-derived mutant resistant to DR5-agonistic antibody-mediated cytotoxicity. (a) Workflow of establishing Jurkat mutant (JurkatR) with decreased sensitivity to zaptuzumab, a DR5-specific agonistic antibody. (b) Sensitivity of wild-type Jurkat and JurkatR to zaptuzumab was determined using the CCK8 method. IC50 values were indicated.

(a)

(b)

(c)